Medicine and Dentistry
Rituximab
100%
In Vitro
100%
Bortezomib
100%
Programmed Cell Death
100%
Cyclophosphamide
100%
Mantle Cell Lymphoma
100%
Mantle Cell Lymphoma Cell
100%
Tumor Cell
20%
Primary Tumor
20%
Western Blot
20%
Therapeutic Modality
20%
Event Free Survival
20%
B-Cell Lymphoma
20%
SCID Mouse
20%
Spontaneous Remission
20%
Growth Inhibition
20%
Proteasome Inhibitor
20%
Poly ADP Ribose Polymerase
20%
Caspase Inhibitor
20%
Caspase 8
20%
Tumor
20%
CD20 Antibody
20%
Mantle Cell Lymphoma Cell Line
20%
Keyphrases
Rituximab
100%
Bortezomib
100%
Apoptosis
100%
Cyclophosphamide
100%
Lymphoma Cells
100%
Mantle Cell Lymphoma
100%
Induced Apoptosis
22%
Complete Remission
22%
Increased Dose
11%
Chemotherapy
11%
Western Blot Analysis
11%
Caspase-8
11%
Protease Inhibitors
11%
Therapeutic Modalities
11%
Event-free Survival
11%
SCID Mice
11%
Fixed-dose Combination
11%
Severe Toxicity
11%
New Regimen
11%
Poor Clinical Outcomes
11%
Growth Inhibition
11%
Duration of Response
11%
Poly(ADP-ribose) Polymerase
11%
Pan-caspase Inhibitor
11%
Aggressive B-cell Lymphoma
11%
Anti-CD20 Antibody
11%
Subcutaneous Tumor
11%
Primary Tumor Cells
11%
Cytoreductive Chemotherapy
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Bortezomib
100%
Cyclophosphamide
100%
Mantle Cell Lymphoma
100%
Chemotherapy
22%
Remission
22%
Western Blot
11%
Caspase 8
11%
Primary Tumor
11%
Event Free Survival
11%
SCID Mouse
11%
Caspase Inhibitor
11%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
11%
B Cell Lymphoma
11%
Proteasome Inhibitor
11%
CD20 Antibody
11%